Zhang Zhen-Lian, Zhang Cui-Zhen, Li Yan, Zhao Zhen-Hui, Yang Shun-E
Department of Lymphoma, The Third Clinical Medicine College of Xinjiang Medical University, Xinjiang.
Department of Medical Laboratory, Chengdu Shuangliu District Maternal and Child Health Hospital, Sichuan.
Medicine (Baltimore). 2018 Apr;97(17):e0317. doi: 10.1097/MD.0000000000010317.
Estrogen has played an important role in the development of breast cancer. ER-α PvuII gene polymorphism is in close association with the occurrence risk of breast cancer, but no consensus has been achieved currently.
PubMed, Embase, China National Knowledge Infrastructure (CNKI) database, Wanfang database, and VIP database were retrieved to collect the case-control studies on association between ERα gene Pvu II polymorphism and breast cancer risk published before September 1, 2017. Newcastle-Ottawa Scale (NOS) was used to assess the quality of the literatures, Stata 14.0 software was applied for meta-analysis, and the pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated. The subgroup analysis was performed to assess the confounding factors, followed by assessment of publication bias and sensitivity analysis.
A total of 26 studies were enrolled in the analysis based on inclusion criteria, which included 15,360 patients and 26,423 controls. The results demonstrated that ERα gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in 3 genetic models (C vs T, OR = 0.962, 95% CI = 0.933-0.992, P = .012; CC vs TT, OR = 0.911, 95% CI = 0.856-0.969, P = .003; CC vs TT/CT, OR = 0.923, 95% CI = 0.874-0.975, P = .004). Subgroup analysis was conducted on the basis of ethnicity and source of controls, whose results illustrated that ERα gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in Asians rather than in Caucasians (CC vs TT, OR = 0.862, 95% CI = 0.750-0.922, P = .038; CC vs TT/CT, OR = 0.851, 95% CI = 0.755-0.959, P = .008). In population-based subgroup rather than in hospital-based subgroup, ERα gene Pvu II polymorphism was in significant association with the decrease of breast cancer risk in the allele model, homozygous model, dominant model, and recessive model (C vs T, OR = 0.943, 95% CI = 0.911-0.977, P = .001; CC vs TT, OR = 0.878, 95% CI = 0.817-0.944, P = .000; CC/CT vs TT, OR = 0.936, 95% CI = 0.881-0.994, P = .031; CC vs TT/CT, OR = 0.902, 95% CI = 0.847-0.960, P = .001).
ERα gene Pvu II polymorphism exerts an important function in the progression of breast cancer.
雌激素在乳腺癌的发生发展中起重要作用。雌激素受体α（ER-α）PvuII基因多态性与乳腺癌发生风险密切相关，但目前尚未达成共识。
检索PubMed、Embase、中国知网（CNKI）数据库、万方数据库和维普数据库，收集2017年9月1日前发表的关于ERα基因Pvu II多态性与乳腺癌风险关联的病例对照研究。采用纽卡斯尔-渥太华量表（NOS）评估文献质量，应用Stata 14.0软件进行荟萃分析，计算合并比值比（OR）和95%置信区间（95%CI）。进行亚组分析以评估混杂因素，随后评估发表偏倚和敏感性分析。
根据纳入标准，共纳入26项研究进行分析，包括15360例患者和26423例对照。结果表明，在3种遗传模型中，ERα基因Pvu II多态性与乳腺癌风险降低显著相关（C与T比较，OR = 0.962，95%CI = 0.933 - 0.992，P = 0.012；CC与TT比较，OR = 0.911，95%CI = 0.856 - 0.969，P = 0.003；CC与TT/CT比较，OR = 0.923，95%CI = 0.874 - 0.975，P = 0.004）。根据种族和对照来源进行亚组分析，结果表明，ERα基因Pvu II多态性与亚洲人而非白种人的乳腺癌风险降低显著相关（CC与TT比较，OR = 0.862，95%CI = 0.750 - 0.922，P = 0.038；CC与TT/CT比较，OR = 0.851，95%CI = 0.755 - 0.959，P = 0.008）。在基于人群的亚组而非基于医院的亚组中，ERα基因Pvu II多态性在等位基因模型、纯合子模型、显性模型和隐性模型中与乳腺癌风险降低显著相关（C与T比较，OR = 0.943，95%CI = 0.911 - 0.977，P = 0.001；CC与TT比较，OR = 0.878，95%CI = 0.817 - 0.944，P = 0.000；CC/CT与TT比较，OR = 0.936，95%CI = 0.881 - 0.994，P = 0.031；CC与TT/CT比较，OR = 0.902，95%CI = 0.847 - 0.960，P = 0.001）。
ERα基因Pvu II多态性在乳腺癌进展中发挥重要作用。
